Simultaneous determination of canrenone, digoxin and tolvaptan by UHPLC–MS/MS: application in heart failure patients

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Wu MY, Chen TT, Chen YC et al. Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis. PloS ONE 12(9), e0184380 (2017).
  MedlineGoogle Scholar
• 2. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14), 1977–2016 (2009).
  MedlineGoogle Scholar
• 3. Howlett JG. Current treatment options for early management in acute decompensated heart failure. Can. J. Cardiol. 24(Suppl. B), 9B–14B (2008).
  Medline CASGoogle Scholar
• 4. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709–717 (1999).
  Medline CASGoogle Scholar
• 5. Johannsen JO, Reuter H, Hoffmann F et al. Reliable and easy-to-use LC–MS/MS-method for simultaneous determination of the antihypertensives metoprolol, amlodipine, canrenone and hydrochlorothiazide in patients with therapy-refractory arterial hypertension. J. Pharm. Biomed. Anal. 164, 373–381 (2019).
  Medline CASGoogle Scholar
• 6. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J. Clin. Pharmacol. 47(12), 1498–1507 (2007).
  Medline CASGoogle Scholar
• 7. Bhatt PR, McNeely EB, Lin TE, Adams KF, Patterson JH. Review of tolvaptan's pharmacokinetic and pharmacodynamic properties and drug interactions. J. Clin. Med. 3(4), 1276–1290 (2014).
  Medline CASGoogle Scholar
• 8. Cheitlin MD. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. Yearbook Cardiol. 2008, 386–388 (2008).
  Google Scholar
• 9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336(8), 525–33 (1997).
  MedlineGoogle Scholar
• 10. Li S, Liu G, Jia J et al. Therapeutic monitoring of serum digoxin for patients with heart failure using a rapid LC–MS/MS method. Clin. Biochem. 43(3), 307–313 (2010).
  Medline CASGoogle Scholar
• 11. McMurray J, Adamopoulos S, Anker S et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Revista Española de Cardiología (English Edition). 65(10), 938 (2012). • Guidelines for the treatment of heart failure.
  Google Scholar
• 12. Wang M-T, Su C-Y, Chan ALF, Lian P-W, Leu H-B, Hsu Y-J. Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study. Br. J. Clin. Pharmacol. 70(2), 258–267 (2010).
  Medline CASGoogle Scholar
• 13. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J. Clin. Pharm. Ther. 30(1), 13–20 (2005).
  Medline CASGoogle Scholar
• 14. Magro L, Conforti A, Del Zotti F et al. Identification of severe potential drug–drug interactions using an Italian general-practitioner database. Eur. J. Clin. Pharmacol. 64(3), 303–309 (2008).
  Medline CASGoogle Scholar
• 15. Morgan DB, Davidson C. Hypokalaemia and diuretics: an analysis of publications. Br. Med. J. 280(6218), 905–908 (1980).
  Medline CASGoogle Scholar
• 16. Eichhorn EJ, Gheorghiade M. Digoxin. Prog. Cardiovasc. Dis. 44(4), 251–266 (2002).
  Medline CASGoogle Scholar
• 17. Lim P, Jacob E. Magnesium deficiency in patients on long-term diuretic therapy for heart failure. Br. Med. J. 3(5827), 620–622 (1972).
  Medline CASGoogle Scholar
• 18. Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. Arch. Intern. Med. 145(4), 655–656 (1985).
  Medline CASGoogle Scholar
• 19. Shoaf SE, Ohzone Y, Ninomiya S et al. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J. Clin. Pharmacol. 51(5), 761–769 (2011). •• Article about drug–drug interaction between tolvaptan and digoxin and potential mechanism for this phenomenon.
  Medline CASGoogle Scholar
• 20. Fenster PE, Hager WD, Goodman MM. Digoxin-quinidine-spironolactone interaction. Clin. Pharmacol. Ther. 36(1), 70–73 (1984).
  Medline CASGoogle Scholar
• 21. Hedman A, Angelin B, Arvidsson A et al. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur. J. Clin. Pharmacol. 42(5), 481–485 (1992).
  Medline CASGoogle Scholar
• 22. Kirby BJ, Kalhorn T, Hebert M, Easterling T, Unadkat JD. Sensitive and specific LC–MS assay for quantification of digoxin in human plasma and urine. Biomed. Chromatogr. 22(7), 712–718 (2008).
  Medline CASGoogle Scholar
• 23. The Pharmacopoeia of People's Republic of China. In: Biological samples quantitative analysis method validation guidelines. Chinese Pharmacopoeia Commission, China Food and Drug Administration, Beijing, China (2015).
  Google Scholar
• 24. Jiang J, Tian L, Huang Y, Yan Y, Li Y. A rapid and sensitive LC–MS/MS-ESI method for the determination of tolvaptan and its two main metabolites in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1027, 158–164 (2016).
  Medline CASGoogle Scholar
• 25. Naguib IA, Abdelaleem EA, Emam AA, Ali NW, Abdallah FF. Development and validation of HPTLC and green HPLC methods for determination of furosemide, spironolactone and canrenone, in pure forms, tablets and spiked human plasma. Biomed. Chromatogr. 32(10), e4304 (2018).
  MedlineGoogle Scholar
• 26. Furukawa M, Miyata K, Kawasome C et al. Liquid chromatography-tandem mass spectrometry method for determining tolvaptan and its nine metabolites in rat serum: application to a pharmacokinetic study. Arch. Pharm. Res. 37(12), 1578–1587 (2014).
  Medline CASGoogle Scholar
• 27. Avataneo V, De Nicolo A, Rabbia F et al. A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. J. Pharmacol. Toxicol. Methods 94(Pt 2), 29–35 (2018).
  Medline CASGoogle Scholar
• 28. Pei Q, Zhang B, Tan H et al. Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 913–914, 84–89 (2013).
  Medline CASGoogle Scholar
• 29. Dong H, Xu F, Zhang Z, Tian Y, Chen Y. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS. J. Mass. Spectrom. 41(4), 477–486 (2006).
  Medline CASGoogle Scholar
• 30. Huang DM, Zhang TZ, Cui FJ et al. Simultaneous identification and quantification of canrenone and 11-alpha-hydroxy-canrenone by LC–MS and HPLC-UVD. J. Biomed. Biotechnol. 2011, 917232 (2011).
  MedlineGoogle Scholar
• 31. Ahmad N, Ahmad R, Ahmad FJ et al. Poloxamer-chitosan-based naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia. Saudi J. Biol. Sci. 27(1), 500–517 (2020).
  Medline CASGoogle Scholar
• 32. Ahmad N, Ahmad R, Al Qatifi S, Alessa M, Al Hajji H, Sarafroz M. A bioanalytical UHPLC based method used for the quantification of thymoquinone-loaded-PLGA-nanoparticles in the treatment of epilepsy. BMC Chem. 14(1), 10 (2020).
  MedlineGoogle Scholar
• 33. Ahmad N, Ahmad R, Alam MA, Ahmad FJ. Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem. Cent. J. 12(1), 65 (2018).
  Medline CASGoogle Scholar
• 34. Ahmad N, Alam MA, Ahmad R, Naqvi AA, Ahmad FJ. Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer. Artif. Cells Nanomed. Biotechnol. 46(2), 432–446 (2018).
  Medline CASGoogle Scholar